{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:34:21Z","timestamp":1793982861799,"version":"4.8.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010969","name":"Alzheimer Nederland","doi-asserted-by":"publisher","award":["WE.03-2018-05"],"award-info":[{"award-number":["WE.03-2018-05"]}],"id":[{"id":"10.13039\/501100010969","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"publisher","award":["2018-T2\/BMD-11885"],"award-info":[{"award-number":["2018-T2\/BMD-11885"]}],"id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["U19 AG062418"],"award-info":[{"award-number":["U19 AG062418"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diagnosis of Frontotemporal dementia (FTD) and its specific underlying neuropathologies (frontotemporal lobar degeneration; FTLD-Tau and FTLD-TDP) are challenging, and thus, fluid biomarkers are needed to improve diagnostic accuracy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We used proximity extension assays to analyze 665 proteins in cerebrospinal fluid (CSF) samples from a multicenter cohort, which included patients with FTD (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009189), Alzheimer\u2019s Disease dementia (AD;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009232), and cognitively unimpaired individuals (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009196). In a subset, FTLD neuropathology was determined based on phenotype or genotype (FTLD-Tau\u2009=\u200987 and FTLD-TDP\u2009=\u200967). Differences in protein expression profiles were analyzed using nested linear models. Penalized generalized linear modeling was used to identify classification protein panels, which were translated to custom multiplex assays and validated in two clinical cohorts (cohort 1:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009161; cohort 2:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009162), one autopsy-confirmed cohort (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009100), and one genetic cohort (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200955).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty-three proteins were differentially regulated in FTD compared to controls and AD, reflecting axon development, regulation of synapse assembly, and cell-cell adhesion mediator activity pathways. Classification analysis identified a 14- and 13-CSF protein panel that discriminated FTD from controls (FTD diagnostic panel, AUC: 0.96) or AD (FTD differential diagnostic panel, AUC: 0.91). Custom multiplex panels confirmed the strong discriminative performancen between FTD and controls (AUCs\u2009&gt;\u20090.96) and between FTD and AD (AUCs\u2009&gt;\u20090.88) across three validation cohorts, including one with autopsy confirmation (AUCs\u2009&gt;\u20090.90). Validation in genetic FTD (including\n                      <jats:italic>C9orf72<\/jats:italic>\n                      ,\n                      <jats:italic>GRN<\/jats:italic>\n                      , and\n                      <jats:italic>MAPT<\/jats:italic>\n                      mutation carriers) revealed high accuracy of the FTD diagnostic panel in identifying both the presymptomatic (AUCs\u2009&gt;\u20090.95) and symptomatic (AUC: 1) stages. Six proteins were differentially regulated between FTLD-TDP and FTLD-Tau. However, a reproducible classification model could not be generated (AUC: 0.80).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, this study introduces novel FTD-specific biomarker panels with potential use in diagnostic settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13024-025-00882-5","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T11:45:49Z","timestamp":1756295149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of frontotemporal dementia"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9713-116X","authenticated-orcid":false,"given":"Yanaika S.","family":"Hok-A-Hin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7420-6384","authenticated-orcid":false,"given":"Lisa","family":"Vermunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5766-9969","authenticated-orcid":false,"given":"Carel F.W.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L.","family":"van der Ende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9595-7221","authenticated-orcid":false,"given":"Sterre C.M.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4277-0815","authenticated-orcid":false,"given":"Lieke H.","family":"Meeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8180-0158","authenticated-orcid":false,"given":"Julie","family":"de Houwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1989-7527","authenticated-orcid":false,"given":"Harro","family":"Seelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6278-6844","authenticated-orcid":false,"given":"John C.","family":"van Swieten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4862-6777","authenticated-orcid":false,"given":"William T.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2568-5478","authenticated-orcid":false,"given":"Alberto","family":"Lle\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3819-3245","authenticated-orcid":false,"given":"Daniel","family":"Alcolea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0304-9785","authenticated-orcid":false,"given":"Sebastiaan","family":"Engelborghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Sieben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3387-2038","authenticated-orcid":false,"given":"Alice","family":"Chen-Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5599-5098","authenticated-orcid":false,"given":"David J.","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8766-6224","authenticated-orcid":false,"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2464-1905","authenticated-orcid":false,"given":"Yolande A.L.","family":"Pijnenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4061-0837","authenticated-orcid":false,"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2808-3699","authenticated-orcid":false,"given":"Marta","family":"del Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"882_CR1","doi-asserted-by":"crossref","unstructured":"Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF et al. Classification of primary progressive aphasia and its variants. Am Acad Neurol. 2011;76.","DOI":"10.1212\/WNL.0b013e31821103e6"},{"issue":"Pt 9","key":"882_CR2","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456\u201377.","journal-title":"Brain"},{"key":"882_CR3","doi-asserted-by":"crossref","unstructured":"Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B et al. Criteria for the diagnosis of corticobasal degeneration. Am Acad Neurol. 2013;80.","DOI":"10.1212\/WNL.0b013e31827f0fd1"},{"issue":"6","key":"882_CR4","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU Hoglinger","year":"2017","unstructured":"Hoglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853\u201364.","journal-title":"Mov Disord"},{"issue":"4","key":"882_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00401-014-1380-1","volume":"129","author":"DJ Irwin","year":"2015","unstructured":"Irwin DJ, Cairns NJ, Grossman M, McMillan CT, Lee EB, Van Deerlin VM, et al. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol. 2015;129(4):469\u201391.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"882_CR6","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/bpa.12486","volume":"27","author":"DMA Mann","year":"2017","unstructured":"Mann DMA, Snowden JS. Frontotemporal lobar degeneration: pathogenesis, pathology and pathways to phenotype. Brain Pathol. 2017;27(6):723\u201336.","journal-title":"Brain Pathol"},{"issue":"Pt 11","key":"882_CR7","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1093\/brain\/awp214","volume":"132","author":"M Neumann","year":"2009","unstructured":"Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IR. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain. 2009;132(Pt 11):2922\u201331.","journal-title":"Brain"},{"issue":"7","key":"882_CR8","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/nan.12250","volume":"41","author":"T Lashley","year":"2015","unstructured":"Lashley T, Rohrer JD, Mead S, Revesz T. Review: an update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. Neuropathol Appl Neurobiol. 2015;41(7):858\u201381.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"882_CR9","unstructured":"Rohrer JD, Guerreiro R, Vandrovcova J, Uphill J, Reiman D, Beck J et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology. 2009;73."},{"issue":"8","key":"882_CR10","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1007\/s00415-019-09363-4","volume":"266","author":"CV Greaves","year":"2019","unstructured":"Greaves CV, Rohrer JD. An update on genetic frontotemporal dementia. J Neurol. 2019;266(8):2075\u201386.","journal-title":"J Neurol"},{"issue":"3","key":"882_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10048-024-00756-w","volume":"25","author":"FE Pozzi","year":"2024","unstructured":"Pozzi FE, Aprea V, Giovannelli G, Lattuada F, Crivellaro C, Bertola F, et al. Clinical and neuroimaging characterization of the first frontotemporal dementia family carrying the MAPT p.K298E mutation. Neurogenetics. 2024;25(3):215\u201323.","journal-title":"Neurogenetics"},{"key":"882_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.neurobiolaging.2022.12.009","volume":"123","author":"HR Cheng","year":"2023","unstructured":"Cheng HR, Lin RR, Li HL, Xue YY, Gao PR, Chen DF, et al. Identification and functional characterization of novel variants of MAPT and GRN in Chinese patients with frontotemporal dementia. Neurobiol Aging. 2023;123:233\u201343.","journal-title":"Neurobiol Aging"},{"key":"882_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-3-030-51140-1_13","volume":"1281","author":"M Neumann","year":"2021","unstructured":"Neumann M, Lee EB, Mackenzie IR. Frontotemporal lobar degeneration TDP-43-immunoreactive pathological subtypes: clinical and mechanistic significance. Adv Exp Med Biol. 2021;1281:201\u201317.","journal-title":"Adv Exp Med Biol"},{"issue":"11","key":"882_CR14","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1002\/alz.12643","volume":"18","author":"M Del Campo","year":"2022","unstructured":"Del Campo M, Zetterberg H, Gandy S, Onyike CU, Oliveira F, Udeh-Momoh C, et al. New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. Alzheimers Dement. 2022;18(11):2292\u2013307.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"882_CR15","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1136\/jnnp.2006.100669","volume":"78","author":"AD Hutchinson","year":"2007","unstructured":"Hutchinson AD, Mathias JL. Neuropsychological deficits in frontotemporal dementia and alzheimer\u2019s disease: a meta-analytic review. J Neurol Neurosurg Psychiatry. 2007;78(9):917\u201328.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"882_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/13554794.2015.1046458","volume":"22","author":"G Naasan","year":"2016","unstructured":"Naasan G, Rabinovici GD, Ghosh P, Elofson JD, Miller BL, Coppola G, et al. Amyloid in dementia associated with Familial FTLD: not an innocent bystander. Neurocase. 2016;22(1):76\u201383.","journal-title":"Neurocase"},{"key":"882_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fnagi.2013.00006","volume":"5","author":"DJ Irwin","year":"2013","unstructured":"Irwin DJ, Trojanowski JQ, Grossman M. Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from alzheimer\u2019s disease. Front Aging Neurosci. 2013;5:6.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"882_CR18","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","volume":"12","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021;12(1):3400.","journal-title":"Nat Commun"},{"key":"882_CR19","doi-asserted-by":"crossref","unstructured":"Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, and the, NFLG et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 2019;76(9):10354\u20138.","DOI":"10.1001\/jamaneurol.2019.1534"},{"issue":"6","key":"882_CR20","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1093\/brain\/awaa018","volume":"143","author":"S Ducharme","year":"2020","unstructured":"Ducharme S, Dols A, Laforce R, Devenney E, Kumfor F, van den Stock J, et al. Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain. 2020;143(6):1632\u201350.","journal-title":"Brain"},{"issue":"4","key":"882_CR21","doi-asserted-by":"publisher","first-page":"100607","DOI":"10.1016\/j.xcrm.2022.100607","volume":"3","author":"TF Gendron","year":"2022","unstructured":"Gendron TF, Heckman MG, White LJ, Veire AM, Pedraza O, Burch AR, et al. Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Rep Med. 2022;3(4):100607.","journal-title":"Cell Rep Med"},{"issue":"14","key":"882_CR22","doi-asserted-by":"publisher","first-page":"e1231","DOI":"10.1212\/WNL.0000000000005261","volume":"90","author":"LHH Meeter","year":"2018","unstructured":"Meeter LHH, Vijverberg EG, Del Campo M, Rozemuller AJM, Donker Kaat L, de Jong FJ, et al. Clinical value of neurofilament and phospho-tau\/tau ratio in the frontotemporal dementia spectrum. Neurology. 2018;90(14):e1231\u20139.","journal-title":"Neurology"},{"issue":"4","key":"882_CR23","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.dadm.2015.11.001","volume":"1","author":"YA Pijnenburg","year":"2015","unstructured":"Pijnenburg YA, Verwey NA, van der Flier WM, Scheltens P, Teunissen CE. Discriminative and prognostic potential of cerebrospinal fluid phosphotau\/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement (Amst). 2015;1(4):505\u201312.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"11","key":"882_CR24","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1001\/jamaneurol.2022.3265","volume":"79","author":"KAQ Cousins","year":"2022","unstructured":"Cousins KAQ, Shaw LM, Chen-Plotkin A, Wolk DA, Van Deerlin VM, Lee EB, et al. Distinguishing frontotemporal lobar degeneration Tau from TDP-43 using plasma biomarkers. JAMA Neurol. 2022;79(11):1155\u201364.","journal-title":"JAMA Neurol"},{"issue":"4","key":"882_CR25","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/jnnp-2018-318603","volume":"90","author":"P Desmarais","year":"2019","unstructured":"Desmarais P, Rohrer JD, Nguyen QD, Herrmann N, Stuss DT, Lang AE, et al. Therapeutic trial design for frontotemporal dementia and related disorders. J Neurol Neurosurg Psychiatry. 2019;90(4):412\u201323.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"882_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/sciadv.aaz9360","volume":"6","author":"L Higginbotham","year":"2020","unstructured":"Higginbotham L, Ping L, Dammer EB, Duong DM, Zhou M, Gearing M, et al. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic alzheimer\u2019s disease. Sci Adv. 2020;6:43.","journal-title":"Sci Adv"},{"issue":"6","key":"882_CR27","doi-asserted-by":"publisher","first-page":"e9356","DOI":"10.15252\/msb.20199356","volume":"16","author":"JM Bader","year":"2020","unstructured":"Bader JM, Geyer PE, Muller JB, Strauss MT, Koch M, Leypoldt F, et al. Proteome profiling in cerebrospinal fluid reveals novel biomarkers of alzheimer\u2019s disease. Mol Syst Biol. 2020;16(6):e9356.","journal-title":"Mol Syst Biol"},{"issue":"1","key":"882_CR28","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13195-022-01113-5","volume":"14","author":"EB Dammer","year":"2022","unstructured":"Dammer EB, Ping L, Duong DM, Modeste ES, Seyfried NT, Lah JJ, et al. Multi-platform proteomic analysis of alzheimer\u2019s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome. Alzheimers Res Ther. 2022;14(1):174.","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"882_CR29","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/s43587-022-00300-1","volume":"2","author":"M Del Campo","year":"2022","unstructured":"Del Campo M, Peeters CFW, Johnson ECB, Vermunt L, Hok-A-Hin YS, van Nee M, et al. CSF proteome profiling across the alzheimer\u2019s disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels. Nat Aging. 2022;2(11):1040\u201353.","journal-title":"Nat Aging"},{"key":"882_CR30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.dadm.2015.12.004","volume":"2","author":"CE Teunissen","year":"2016","unstructured":"Teunissen CE, Elias N, Koel-Simmelink MJ, Durieux-Lu S, Malekzadeh A, Pham TV, et al. Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. Alzheimers Dement (Amst). 2016;2:86\u201394.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"4","key":"882_CR31","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/acn3.745","volume":"6","author":"EL van der Ende","year":"2019","unstructured":"van der Ende EL, Meeter LH, Stingl C, van Rooij JGJ, Stoop MP, Nijholt DAT, et al. Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics. Ann Clin Transl Neurol. 2019;6(4):698\u2013707.","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"882_CR32","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/acn3.629","volume":"5","author":"M Del Campo","year":"2018","unstructured":"Del Campo M, Galimberti D, Elias N, Boonkamp L, Pijnenburg YA, van Swieten JC, et al. Novel CSF biomarkers to discriminate FTLD and its pathological subtypes. Ann Clin Transl Neurol. 2018;5(10):1163\u201375.","journal-title":"Ann Clin Transl Neurol"},{"issue":"6","key":"882_CR33","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1136\/jnnp-2019-322493","volume":"91","author":"EL van der Ende","year":"2020","unstructured":"van der Ende EL, Xiao M, Xu D, Poos JM, Panman JL, Jiskoot LC, et al. Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2020;91(6):612\u201321.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"882_CR34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3233\/JAD-220318","volume":"90","author":"K Bolsewig","year":"2022","unstructured":"Bolsewig K, Hok AHYS, Sepe FN, Boonkamp L, Jacobs D, Bellomo G, et al. A combination of neurofilament light, glial fibrillary acidic protein, and neuronal Pentraxin-2 discriminates between frontotemporal dementia and other dementias. J Alzheimers Dis. 2022;90(1):363\u201380.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"882_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-017-0226-4","volume":"12","author":"F Llorens","year":"2017","unstructured":"Llorens F, Thune K, Tahir W, Kanata E, Diaz-Lucena D, Xanthopoulos K, et al. YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol Neurodegener. 2017;12(1):83.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"882_CR36","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1038\/s41467-023-41122-y","volume":"14","author":"M Del Campo","year":"2023","unstructured":"Del Campo M, Vermunt L, Peeters CFW, Sieben A, Hok AHYS, Lleo A, et al. CSF proteome profiling reveals biomarkers to discriminate dementia with lewy bodies from alzheimer s disease. Nat Commun. 2023;14(1):5635.","journal-title":"Nat Commun"},{"issue":"3","key":"882_CR37","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JAD-170850","volume":"62","author":"WM van der Flier","year":"2018","unstructured":"van der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. J Alzheimers Dis. 2018;62(3):1091\u2013111.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"882_CR38","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00401-007-0280-z","volume":"114","author":"M Ingelsson","year":"2007","unstructured":"Ingelsson M, Ramasamy K, Russ C, Freeman SH, Orne J, Raju S, et al. Increase in the relative expression of Tau with four microtubule binding repeat regions in frontotemporal Lobar degeneration and progressive supranuclear palsy brains. Acta Neuropathol. 2007;114(5):471\u20139.","journal-title":"Acta Neuropathol"},{"key":"882_CR39","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.trci.2019.09.005","volume":"5","author":"D Alcolea","year":"2019","unstructured":"Alcolea D, Clarimon J, Carmona-Iragui M, Illan-Gala I, Morenas-Rodriguez E, Barroeta I, et al. The Sant Pau initiative on neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimers Dement (N Y). 2019;5:597\u2013609.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"8","key":"882_CR40","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","volume":"6","author":"B Dubois","year":"2007","unstructured":"Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of alzheimer\u2019s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734\u201346.","journal-title":"Lancet Neurol"},{"issue":"1","key":"882_CR41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00401-007-0237-2","volume":"114","author":"NJ Cairns","year":"2007","unstructured":"Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the consortium for frontotemporal lobar degeneration. Acta Neuropathol. 2007;114(1):5\u201322.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"882_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National institute on aging-alzheimer\u2019s association guidelines for the neuropathologic assessment of alzheimer\u2019s disease: a practical approach. Acta Neuropathol. 2012;123(1):1\u201311.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"882_CR43","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/alz.12033","volume":"16","author":"T Miyagawa","year":"2020","unstructured":"Miyagawa T, Brushaber D, Syrjanen J, Kremers W, Fields J, Forsberg LK, et al. Utility of the global CDR plus NACC FTLD rating and development of scoring rules: data from the ARTFL\/LEFFTDS consortium. Alzheimers Dement. 2020;16(1):106\u201317.","journal-title":"Alzheimers Dement"},{"key":"882_CR44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-1-4939-9706-0_2","volume":"2044","author":"YS Hok-A-Hin","year":"2019","unstructured":"Hok-A-Hin YS, Willemse EAJ, Teunissen CE, Del Campo M. Guidelines for CSF processing and biobanking: impact on the identification and development of optimal CSF protein biomarkers. Methods Mol Biol. 2019;2044:27\u201350.","journal-title":"Methods Mol Biol"},{"issue":"3","key":"882_CR45","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1373\/clinchem.2017.281055","volume":"64","author":"BM Tijms","year":"2018","unstructured":"Tijms BM, Willemse EAJ, Zwan MD, Mulder SD, Visser PJ, van Berckel BNM, et al. Unbiased approach to counteract upward drift in cerebrospinal fluid Amyloid-beta 1\u201342 analysis results. Clin Chem. 2018;64(3):576\u201385.","journal-title":"Clin Chem"},{"issue":"11","key":"882_CR46","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1002\/acn3.51676","volume":"9","author":"L Vermunt","year":"2022","unstructured":"Vermunt L, Otte M, Verberk IMW, Killestein J, Lemstra AW, van der Flier WM, et al. Age- and disease-specific reference values for neurofilament light presented in an online interactive support interface. Ann Clin Transl Neurol. 2022;9(11):1832\u20137.","journal-title":"Ann Clin Transl Neurol"},{"key":"882_CR47","unstructured":"Proteomics O. Development and validation of customized PEA biomarker panels with clinical utility."},{"key":"882_CR48","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Royal Stat Soc Ser B (Methodological). 1995;57."},{"key":"882_CR49","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.dadm.2017.07.006","volume":"8","author":"FA de Leeuw","year":"2017","unstructured":"de Leeuw FA, Peeters CFW, Kester MI, Harms AC, Struys EA, Hankemeier T, et al. Blood-based metabolic signatures in alzheimer\u2019s disease. Alzheimers Dement (Amst). 2017;8:196\u2013207.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"882_CR50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"J Friedman","year":"2010","unstructured":"Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):22.","journal-title":"J Stat Softw"},{"issue":"1","key":"882_CR51","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.","journal-title":"Nat Commun"},{"key":"882_CR52","doi-asserted-by":"crossref","unstructured":"Karlsson L, Vogel J, Arvidsson I, \u00c5str\u00f6m K, Janelidze S, Blennow K et al. Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases. BioRxiv. 2023.","DOI":"10.1101\/2023.06.08.544222"},{"issue":"1","key":"882_CR53","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S0021-9258(18)52407-8","volume":"266","author":"M Poe","year":"1991","unstructured":"Poe M, Blake JT, Boulton DA, Gammon M, Sigal NH, Wu JK, et al. Human cytotoxic lymphocyte granzyme B. Its purification from granules and the characterization of substrate and inhibitor specificity. J Biol Chem. 1991;266(1):98\u2013103.","journal-title":"J Biol Chem"},{"issue":"2","key":"882_CR54","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3233\/JAD-130647","volume":"37","author":"B Mroczko","year":"2013","unstructured":"Mroczko B, Groblewska M, Barcikowska M. The role of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the pathophysiology of neurodegeneration: a literature study. J Alzheimers Dis. 2013;37(2):273\u201383.","journal-title":"J Alzheimers Dis"},{"issue":"35","key":"882_CR55","doi-asserted-by":"publisher","first-page":"37069","DOI":"10.1074\/jbc.M402507200","volume":"279","author":"ML Spencer","year":"2004","unstructured":"Spencer ML, Theodosiou M, Noonan DJ. NPDC-1, a novel regulator of neuronal proliferation, is degraded by the ubiquitin\/proteasome system through a PEST degradation motif. J Biol Chem. 2004;279(35):37069\u201378.","journal-title":"J Biol Chem"},{"issue":"5","key":"882_CR56","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41419-019-1578-1","volume":"10","author":"DS Pei","year":"2019","unstructured":"Pei DS, Jia PP, Luo JJ, Liu W, Strauss PR. AP endonuclease 1 (Apex1) influences brain development linking oxidative stress and DNA repair. Cell Death Dis. 2019;10(5):348.","journal-title":"Cell Death Dis"},{"issue":"5","key":"882_CR57","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrm1911","volume":"7","author":"AK Olsson","year":"2006","unstructured":"Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7(5):359\u201371.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"882_CR58","doi-asserted-by":"crossref","unstructured":"Huang X, Feng Z, Jiang Y, Li J, Xiang Q, Guo S et al. VSIG4 mediates transcriptional Inhibition of Nlrp3 and Il-1b in macrophages. Sci Adv. 2019;5.","DOI":"10.1126\/sciadv.aau7426"},{"issue":"29","key":"882_CR59","doi-asserted-by":"publisher","first-page":"22121","DOI":"10.1074\/jbc.M002788200","volume":"275","author":"JQ Zhang","year":"2000","unstructured":"Zhang JQ, Nicoll G, Jones C, Crocker PR. Siglec-9, a novel Sialic acid binding member of the Immunoglobulin superfamily expressed broadly on human blood leukocytes. J Biol Chem. 2000;275(29):22121\u20136.","journal-title":"J Biol Chem"},{"key":"882_CR60","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1073\/pnas.0703893104","volume":"104","author":"Q Yan","year":"2007","unstructured":"Yan Q, Malashkevich VN, Fedorov A, Fedorov E, Cao E, Lary JW, et al. Structure of CD84 provides insight into SLAM family function. PNAS. 2007;104:25.","journal-title":"PNAS"},{"issue":"5","key":"882_CR61","first-page":"969","volume":"26","author":"Y Tanaka","year":"2017","unstructured":"Tanaka Y, Suzuki G, Matsuwaki T, Hosokawa M, Serrano G, Beach TG, et al. Progranulin regulates lysosomal function and biogenesis through acidification of lysosomes. Hum Mol Genet. 2017;26(5):969\u201388.","journal-title":"Hum Mol Genet"},{"issue":"10","key":"882_CR62","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.it.2004.08.006","volume":"25","author":"U Kishore","year":"2004","unstructured":"Kishore U, Gaboriaud C, Waters P, Shrive AK, Greenhough TJ, Reid KB, et al. C1q and tumor necrosis factor superfamily: modularity and versatility. Trends Immunol. 2004;25(10):551\u201361.","journal-title":"Trends Immunol"},{"issue":"8","key":"882_CR63","doi-asserted-by":"publisher","first-page":"e23070","DOI":"10.1371\/journal.pone.0023070","volume":"6","author":"M Goel","year":"2011","unstructured":"Goel M, Sienkiewicz AE, Picciani R, Lee RK, Bhattacharya SK. Cochlin induced TREK-1 co-expression and Annexin A2 secretion: role in trabecular meshwork cell elongation and motility. PLoS ONE. 2011;6(8):e23070.","journal-title":"PLoS ONE"},{"issue":"2","key":"882_CR64","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3233\/JAD-201565","volume":"81","author":"G Bostrom","year":"2021","unstructured":"Bostrom G, Freyhult E, Virhammar J, Alcolea D, Tumani H, Otto M, et al. Different inflammatory signatures in alzheimer\u2019s disease and frontotemporal dementia cerebrospinal fluid. J Alzheimers Dis. 2021;81(2):629\u201340.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"882_CR65","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s40478-022-01499-1","volume":"10","author":"MO Mol","year":"2022","unstructured":"Mol MO, Miedema SSM, Melhem S, Li KW, Koopmans F, Seelaar H, et al. Proteomics of the dentate gyrus reveals semantic dementia specific molecular pathology. Acta Neuropathol Commun. 2022;10(1):190.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"882_CR66","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s40478-022-01387-8","volume":"10","author":"SSM Miedema","year":"2022","unstructured":"Miedema SSM, Mol MO, Koopmans FTW, Hondius DC, van Nierop P, Menden K, et al. Distinct cell type-specific protein signatures in GRN and MAPT genetic subtypes of frontotemporal dementia. Acta Neuropathol Commun. 2022;10(1):100.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"882_CR67","doi-asserted-by":"publisher","first-page":"48","DOI":"10.15252\/emmm.201708202","volume":"10","author":"ME Umoh","year":"2018","unstructured":"Umoh ME, Dammer EB, Dai J, Duong DM, Lah JJ, Levey AI, et al. A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Mol Med. 2018;10(1):48\u201362.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"882_CR68","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s40478-022-01458-w","volume":"10","author":"RB Mofrad","year":"2022","unstructured":"Mofrad RB, Del Campo M, Peeters CFW, Meeter LHH, Seelaar H, Koel-Simmelink M, et al. Plasma proteome profiling identifies changes associated to AD but not to FTD. Acta Neuropathol Commun. 2022;10(1):148.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"882_CR69","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12974-023-02796-9","volume":"20","author":"YS Hok-A-Hin","year":"2023","unstructured":"Hok-A-Hin YS, Del Campo M, Boiten WA, Stoops E, Vanhooren M, Lemstra AW, et al. Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in alzheimer\u2019s disease. J Neuroinflammation. 2023;20(1):107.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"882_CR70","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13195-019-0508-x","volume":"11","author":"S Zhang","year":"2019","unstructured":"Zhang S, Zhao J, Zhang Y, Zhang Y, Cai F, Wang L, et al. Upregulation of MIF as a defense mechanism and a biomarker of alzheimer\u2019s disease. Alzheimers Res Ther. 2019;11(1):54.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"882_CR71","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40035-020-00198-y","volume":"9","author":"J Remnestal","year":"2020","unstructured":"Remnestal J, Oijerstedt L, Ullgren A, Olofsson J, Bergstrom S, Kultima K, et al. Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers. Transl Neurodegener. 2020;9(1):27.","journal-title":"Transl Neurodegener"},{"issue":"3","key":"882_CR72","doi-asserted-by":"publisher","first-page":"e209585","DOI":"10.1212\/WNL.0000000000209585","volume":"103","author":"A Wise","year":"2024","unstructured":"Wise A, Li J, Yamakawa M, Loureiro J, Peterson B, Worringer K, et al. CSF proteomics in patients with progressive supranuclear palsy. Neurology. 2024;103(3):e209585.","journal-title":"Neurology"},{"issue":"12","key":"882_CR73","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.1007\/s00415-024-12694-6","volume":"271","author":"B Muqaku","year":"2024","unstructured":"Muqaku B, Anderl-Straub S, Werner L, Nagl M, Otto M, Teunissen CE, et al. Contactin proteins in cerebrospinal fluid show different alterations in dementias. J Neurol. 2024;271(12):7516\u201324.","journal-title":"J Neurol"},{"issue":"7","key":"882_CR74","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1093\/brain\/awac024","volume":"145","author":"PV Martino Adami","year":"2022","unstructured":"Martino Adami PV, Orellana A, Garcia P, Kleineidam L, Alarcon-Martin E, Montrreal L, et al. Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the alzheimer\u2019s type. Brain. 2022;145(7):2507\u201317.","journal-title":"Brain"},{"issue":"1","key":"882_CR75","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-019-0562-4","volume":"12","author":"S Abu-Rumeileh","year":"2019","unstructured":"Abu-Rumeileh S, Steinacker P, Polischi B, Mammana A, Bartoletti-Stella A, Oeckl P, et al. CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. Alzheimers Res Ther. 2019;12(1):2.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"882_CR76","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1136\/jnnp-2017-317138","volume":"89","author":"P Steinacker","year":"2018","unstructured":"Steinacker P, Verde F, Fang L, Feneberg E, Oeckl P, Roeber S, et al. Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. J Neurol Neurosurg Psychiatry. 2018;89(3):239\u201347.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"882_CR77","unstructured":"van der Ende EL. Veld S, Hanskamp I, van der Lee S, Dijkstra JIR, Hok AHYS, CSF proteomics in autosomal dominant Alzheimer\u2019s disease highlights parallels with sporadic disease. Brain. 2023."},{"issue":"1","key":"882_CR78","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s40478-019-0795-2","volume":"7","author":"CD Whelan","year":"2019","unstructured":"Whelan CD, Mattsson N, Nagle MW, Vijayaraghavan S, Hyde C, Janelidze S, et al. Multiplex proteomics identifies novel CSF and plasma biomarkers of early alzheimer\u2019s disease. Acta Neuropathol Commun. 2019;7(1):169.","journal-title":"Acta Neuropathol Commun"},{"key":"882_CR79","doi-asserted-by":"crossref","unstructured":"Guo Y, Chen SD, You J, Huang SY, Chen YL, Zhang Y et al. Multiplex cerebrospinal fluid proteomics identifies biomarkers for diagnosis and prediction of Alzheimer\u2019s disease. Nat Hum Behav. 2024.","DOI":"10.1038\/s41562-024-01924-6"},{"issue":"Pt 6","key":"882_CR80","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1242\/jcs.026096","volume":"121","author":"P Bovolenta","year":"2008","unstructured":"Bovolenta P, Esteve P, Ruiz JM, Cisneros E, Lopez-Rios J. Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J Cell Sci. 2008;121(Pt 6):737\u201346.","journal-title":"J Cell Sci"},{"issue":"6","key":"882_CR81","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/cbf.3530","volume":"38","author":"F Hadi","year":"2020","unstructured":"Hadi F, Akrami H, Shahpasand K, Fattahi MR. Wnt signalling pathway and Tau phosphorylation: A comprehensive study on known connections. Cell Biochem Funct. 2020;38(6):686\u201394.","journal-title":"Cell Biochem Funct"},{"issue":"1","key":"882_CR82","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13195-022-01042-3","volume":"14","author":"A Sogorb-Esteve","year":"2022","unstructured":"Sogorb-Esteve A, Nilsson J, Swift IJ, Heller C, Bocchetta M, Russell LL, et al. Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia. Alzheimers Res Ther. 2022;14(1):118.","journal-title":"Alzheimers Res Ther"},{"key":"882_CR83","unstructured":"Saloner R. Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal Lobar degeneration. Preprint Biorxv. 2024."},{"issue":"1","key":"882_CR84","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13195-018-0364-0","volume":"10","author":"J Goossens","year":"2018","unstructured":"Goossens J, Bjerke M, Van Mossevelde S, Van den Bossche T, Goeman J, De Vil B, et al. Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal Lobar degeneration. Alzheimers Res Ther. 2018;10(1):31.","journal-title":"Alzheimers Res Ther"},{"key":"882_CR85","unstructured":"Meda F, Simren J, Borroni B, Cantoni V, Archetti S, Biasiotto G et al. Analytical and clinical validation of a blood progranulin ELISA in frontotemporal dementias. Clin Chem Lab Med. 2023."},{"issue":"1","key":"882_CR86","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40478-023-01571-4","volume":"11","author":"SE Davis","year":"2023","unstructured":"Davis SE, Cook AK, Hall JA, Voskobiynyk Y, Carullo NV, Boyle NR, et al. Patients with sporadic FTLD exhibit similar increases in lysosomal proteins and storage material as patients with FTD due to GRN mutations. Acta Neuropathol Commun. 2023;11(1):70.","journal-title":"Acta Neuropathol Commun"},{"issue":"Pt 11","key":"882_CR87","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1093\/brain\/awl271","volume":"129","author":"IR Mackenzie","year":"2006","unstructured":"Mackenzie IR, Baker M, Pickering-Brown S, Hsiung GY, Lindholm C, Dwosh E, et al. The neuropathology of frontotemporal Lobar degeneration caused by mutations in the progranulin gene. Brain. 2006;129(Pt 11):3081\u201390.","journal-title":"Brain"},{"issue":"784","key":"882_CR88","doi-asserted-by":"publisher","first-page":"eadm9654","DOI":"10.1126\/scitranslmed.adm9654","volume":"17","author":"A Sogorb-Esteve","year":"2025","unstructured":"Sogorb-Esteve A, Weiner S, Simr\u00e9n J, Swift IJ, Bocchetta M, Todd EG, et al. Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes. Sci Transl Med. 2025;17(784):eadm9654.","journal-title":"Sci Transl Med"},{"issue":"7784","key":"882_CR89","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","volume":"575","author":"C Ising","year":"2019","unstructured":"Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, et al. NLRP3 inflammasome activation drives Tau pathology. Nature. 2019;575(7784):669\u201373.","journal-title":"Nature"},{"issue":"6","key":"882_CR90","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1001\/jamaneurol.2018.0118","volume":"75","author":"A Lleo","year":"2018","unstructured":"Lleo A, Irwin DJ, Illan-Gala I, McMillan CT, Wolk DA, Lee EB, et al. A 2-Step cerebrospinal algorithm for the selection of frontotemporal Lobar degeneration subtypes. JAMA Neurol. 2018;75(6):738\u201345.","journal-title":"JAMA Neurol"},{"issue":"10","key":"882_CR91","doi-asserted-by":"publisher","first-page":"e0185797","DOI":"10.1371\/journal.pone.0185797","volume":"12","author":"F Palluzzi","year":"2017","unstructured":"Palluzzi F, Ferrari R, Graziano F, Novelli V, Rossi G, Galimberti D, et al. A novel network analysis approach reveals DNA damage, oxidative stress and calcium\/camp homeostasis-associated biomarkers in frontotemporal dementia. PLoS ONE. 2017;12(10):e0185797.","journal-title":"PLoS ONE"},{"issue":"8","key":"882_CR92","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1093\/brain\/awad078","volume":"146","author":"M Malpetti","year":"2023","unstructured":"Malpetti M, Cope TE, Street D, Jones PS, Hezemans FH, Mak E, et al. Microglial activation in the frontal cortex predicts cognitive decline in frontotemporal dementia. Brain. 2023;146(8):3221\u201331.","journal-title":"Brain"},{"issue":"5","key":"882_CR93","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/glia.20478","volume":"55","author":"RK Nuttall","year":"2007","unstructured":"Nuttall RK, Silva C, Hader W, Bar-Or A, Patel KD, Edwards DR, et al. Metalloproteinases are enriched in microglia compared with leukocytes and they regulate cytokine levels in activated microglia. Glia. 2007;55(5):516\u201326.","journal-title":"Glia"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00882-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-025-00882-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00882-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:46:13Z","timestamp":1781610373000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13024-025-00882-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["882"],"URL":"https:\/\/doi.org\/10.1186\/s13024-025-00882-5","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval was given by the institutional ethical review boards of each center. Written informed consent was obtained from all participants or their authorized representatives.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Y.H., C.P., E.E., S.B., L.M, J.S., J.H., H.R., W.H., A.S., A.C.-P, and D.I. declare no competing interest. M.C. has been an invited speaker at Eisai, is an associate editor at Alzheimer\u00b4s Research & Therapy and has been an invited writer for Springer Healthcare. L.V. received a grant for CORAL consortium by Olink proteomics. D.I. is a Scientific Advisory Board Member for Denali Therapeutics. D.A. participated in advisory boards from Fujirebio-Europe and Roche Diagnostics and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmac\u00e9utica S.L., Zambon S.A.U. and Esteve Pharmaceuticals. S.A. D.A., and A.L. declare a filed patent application (Title: Markers of synaptopathy in neurodegenerative disease; Applicant: Fundaci\u00f3 Institut de Recerca de l\u2019Hospital de la Santa Creu i Sant Pau, Inventors: Olivia BELBIN; Alberto LLE\u00d3; Alejandro BAY\u00c9S; Juan FORTEA; Daniel ALCOLEA; Application number: PCT\/EP2019\/056535; International Publication Number: WO 2019\/175379 A1; Current status: Active. Licensed to ADx Neurociences NV (Ghent, Belgium); this patent is not related to any specific aspect of the current manuscript). S.E. received personal fees from Eisai (paid to institution), personal fees from icometrix (paid to institution), personal fees from Novartis (paid to institution), personal fees from Roche (paid to institution) and personal fees from Roche and personal fees from Biogen, all outside the submitted work. W.F. has performed contract research for Biogen MA Inc, and Boehringer Ingelheim. W.F. has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), Springer Healthcare. W.F. is consultant to Oxford Health Policy Forum CIC, Roche, and Biogen MA Inc. WF participated in advisory boards of Biogen MA Inc and Roche. All funding is paid to her institution. W.F. is a member of the steering committee of PAVE, and Think Brain Health. W.F. was associate editor of Alzheimer\u2019s Research & Therapy in 2020\/2021 and is currently an associate editor at Brain. C.E.T. has a collaboration contract with ADx Neurosciences, Quanterix, and Eli Lilly, performed contract research or received grants from AC-Immune, Axon Neurosciences, Bioconnect, Bioorchestra, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Grifols, Novo Nordisk, PeopleBio, Roche, Toyama, and Vivoryon. She serves on editorial boards of Medidact Neurologie\/Springer, Alzheimer\u2019s Research & Therapy, Neurology: Neuroimmunology & Neuroinflammation, and is editor of a Neuromethods book Springer. She had speaker contracts for Roche, Grifols, and Novo Nordisk.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}